Provided by Tiger Trade Technology Pte. Ltd.

RAPT Therapeutics, Inc.

33.18
-0.8500-2.50%
Volume:351.50K
Turnover:11.67M
Market Cap:919.45M
PE:-5.03
High:35.17
Open:34.14
Low:31.70
Close:34.03
52wk High:42.39
52wk Low:5.67
Shares:27.71M
Float Shares:13.26M
Volume Ratio:0.90
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5969
EPS(LYR):-25.4880
ROE:-85.37%
ROA:-51.35%
PB:6.05
PE(LYR):-1.30

Loading ...

Company Profile

Company Name:
RAPT Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
60
Office Location:
561 Eccles Avenue,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Directors

Name
Position
Brian Wong
Director,President and Chief Executive Officer
Lori Lyons Williams
Chairman of the Board
Ashley Dombkowski
Independent Director
Linda Kozick
Independent Director
Mary Ann Gray
Independent Director
Scott Braunstein
Independent Director
Wendye Robbins
Independent Director

Shareholders

Name
Position
Brian Wong
Director,President and Chief Executive Officer
Rodney Young
Chief Financial Officer
Dirk Brockstedt
Chief Scientific Officer